All News

research2.jpg

Lupus Core Dataset for Research

d EurekAlert!

SLE is a complex and potentially life-threatening autoimmune disease. Part of the complexity stems from how it can differ from person to person – giving rise to marked heterogeneity in not only manifestations, but also in disease course and treatment response.

Read Article
phys.therapy.knee2_.jpg

Physical Therapy Underprescribed

d MedPage Today

Just one patient in six was referred for physical therapy (PT) within 15 days of being treated for knee pain at one major U.S. health system, researchers found, despite nearly universal consensus that PT should be recommended in most cases.

Read Article
tylenol,acetaminophen,pills,tablets

Prenatal acetaminophen linked to increased autism and ADHD

d EurekAlert!

Researchers at the Icahn School of Medicine at Mount Sinai have found that prenatal exposure to acetaminophen may increase the risk of neurodevelopmental disorders, including autism spectrum disorder and attention-deficit/hyperactivity disorder (ADHD), in children.

Read Article
Pills.JIA_.png

Antibiotics are not linked to Autoimmune disease in kids

d EurekAlert!

The global incidence of autoimmune diseases among children has increased over the past few decades.

Read Article
RheumNow Podcast square

Sjögren's Graduates (8.22.2025)

d Jack Cush, MD

Dr. Jack Cush reviews the news, journal reports, FDA approvals, drug safety, and more from this week.

Read Article
Sjogren.eye.mouth

It's now called Sjögren Disease!

d Jack Cush, MD

Sjögren syndrome is now Sjögren disease, according to recommendations stemming from the 2023 International Rome consensus for the nomenclature of Sjögren disease.

Read Article
Antibiotics are not linked to Autoimmune disease in kids The global incidence of autoimmune diseases among children has increased over the past few decades. A study published August 21st in the open-access journal PLOS Medicine by Ju-Young Shin at Sungkyunkwan University, https://t.co/siIDGezw9W
Dr. John Cush RheumNow ( View Tweet)
Study of 90 Still's Dz pts w/ lung disease from AIDA network - mean age 36 yr; 36% male (13% from pediatrics). Lung findings: pleuritis 72%, parenchymal 34%, ARDS 9.5% & pulm HTN 2.3%. Parenchymal involvement assoc w/ sore throat, pericarditis, higher systemic score, but not https://t.co/4YIx2BwADe
Dr. John Cush RheumNow ( View Tweet)
AbbVie announces positive topline results from a 2nd Phase 3 UP-AA Trial evaluating Upadacitinib in Alopecia Areata (AA) - w/ 45% and 55% of severe AA pts rx w/ UPA 15 mg and 30 mg, achieving a SALT score ≤ 201 (80% or more scalp hair coverage) at week 24 https://t.co/8p1FvJx0s0
Dr. John Cush RheumNow ( View Tweet)
Rapid rituximab infusions are safe & efficient. Metanalysis of 7 RCTs, 538 pts w/ autoimmune/rheumatic dz, showed infusions(RTX 1000 mg) of 90-120 min (w/ premedication) had low risk (3-15%) of mild (Grades 1, 2) infusion Rxns; only 6 Grade 3 Rxns https://t.co/uVKuhhc80F https://t.co/NIMMhgIRzH

Links:

Dr. John Cush RheumNow ( View Tweet)
FDA has granted Soligenix "Orphan Drug Designation" to study dusquetide in the treatment of Behçet's dz, based on an 8 patient proof of concept Phase 2a trial. Not yet FDA approved, dusquetide is a short peptide innate defense regulator (IDR). Behcets affects 18K in USA and https://t.co/RzzVuQ6bAB
Dr. John Cush RheumNow ( View Tweet)
Single-center Retrospective study of 4,736 RA, propensity matched 509 w/ RA-ILD vs 509 without ILD. In multivariate analysis RF positivity was an independent risk factor for RA-ILD (adj OR = 1.5) w/ signif nonlinear relationship observed, risk threshold @60 IU/mL Paradoxical https://t.co/0XtWnIsbmK
Dr. John Cush RheumNow ( View Tweet)
Telitacicept, a BLyS (BAFF)/APRIL dual-target fusion drug, announced it has met the primary endpoint in its Phase III clinical trial in treating primary Sjögren's syndrome (pSS) in China. Primary endpoint was the change in ESSDAI score at Week 24. https://t.co/afOgpGLdV1 https://t.co/9EKbbrCgTL

Links:

Dr. John Cush RheumNow ( View Tweet)
Gout Education Card for Patients - Info & Rules #1 https://t.co/uppST8OBLZ https://t.co/3Ry3erNJCL

Links:

Dr. John Cush RheumNow ( View Tweet)
Gout Education Card for Patients - Diagnosis & Management #2 https://t.co/uppST8OBLZ https://t.co/sLF5WPeuA5

Links:

Dr. John Cush RheumNow ( View Tweet)
TriNetX database study shows Beta blocker use assoc w/ more hip replacements (THA). 23K propensity matched pts (mean age 69) on or off BB compared. After 3 yrs BB use was assoc w/ higher risk of THA (HR 1.49; 1.4–1.59), esp w/ alpha-BBs (HR 1.64) https://t.co/W6ocMYI653 https://t.co/EiQ4WH94cD

Links:

Dr. John Cush RheumNow ( View Tweet)
New IDSA recommendation: In hospitalized on systemic steroids w/ severe, critical, progressing COVID-19, when baricitinib or tocilizumab are not available, IDSA guideline panel suggests infliximab. https://t.co/ZCkkZXUDpi https://t.co/gbgkvj5R8Y

Links:

Dr. John Cush RheumNow ( View Tweet)
ChildCAPTURE & BioCAPTURE registry studies of 117 pediatric & 243 young adult Psoriasis pts on biologics (753.4 Pt-Yrs) shows no sex differences in clinical responses, but shows females have more adverse events than males (both cohorts) https://t.co/5at9vCqwIO https://t.co/ScJkIH9G31

Links:

Dr. John Cush RheumNow ( View Tweet)
Uncertainty with immunosuppressive for idiopathic inflammatory myopathies A current Cochrane review suggests a continued unmet need regarding the status and utility of targeted immunosuppressant and immunomodulatory treatments for IIM. https://t.co/evkwbX6U9j https://t.co/2s0Z9Y9Umm

Links:

Dr. John Cush RheumNow ( View Tweet)
Claims data study of 82 399 PsA pts - 542 on combo targeted Rx >3 mos (200 > 6mos). 2 most common combos of apremilast w/ TNFi or IL-17i. Use of combo targeted Tx was not assoc. w/ more serious infxn (RRs 0.53; 0.17-1.63) or opportunistic infx (RR 1.00; 0.09-11.02) @ 3 or 6 mos https://t.co/mkvq1lqt9Y
Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×